A Methodology Study to Assess Muscle Damage After Eccentric Exercise

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 1

Conditions

Tendon Injuries

Treatments

Other: Eccentric exercise

Study type

Interventional

Funder types

Industry

Identifiers

NCT02014662

200794

Details and patient eligibility

About

An isolated bout of unaccustomed maximal eccentric exercise is associated with muscle force loss for 2-4 days, mild reversible muscle tenderness, and ultra-structural damage to the muscle fibers, elevation of muscle proteins in serum, and a detriment in range of motion. This single center, pilot study is designed to optimize conditions for the robust measurement of functional deficits after muscle damage and to identify markers of repair over 22 days to inform future intervention studies. The primary measure will be limb force (assessed electronically from the ergometer), previous studies have demonstrated that functional measures return fairly rapidly, usually between 2-4 days. Additionally, several biomarkers of muscle function will be measured over 22 days, as well as changes in protein synthesis in biopsy samples Deuterium-labelled water (D2O) will be consumed by all study participants from Day-3 through Day 22 to aid in quantifying newly synthesized proteins.

Enrollment

12 patients

Sex

Male

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Males aged between 18 and 35 years of age inclusive, at the time of signing the informed consent, not on a regular exercise program.
Body Mass Index (BMI) 18-27 kilogram per meter square (kg/m^2) with waist circumference <96 centimeter (cm).
Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Based on single or averaged corrected QT interval (QTc) (Bazzett [QTcB] or Fredericia [QTcF]) values of triplicate electrocardiograms (ECGs) obtained over a brief recording period: QTc <450 milliseconds (msec); or QTc < 480 msec in subjects with Bundle Branch Block.
At least a 1year history of no regular (2-3 times per week) exercise and no heavy exertion within past week.

Exclusion criteria

History of keloid scarring
History of dizziness or vertigo
History of bleeding disorders or elevated partial thromboplastin time/international normalized ratio (PTT/INR) at screening, or currently on anticoagulants
Taking anti-inflammatory, glucocorticoid or other pain medication more than 2 times per week over the previous month.
Taking regular statin medication.
Herbal supplement use
History of smoking or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
History of drug or alcohol abuse within 5 years prior to the Screening Period.
History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units. One unit is equivalent to 8 gram (gm) of alcohol: a half-pint (~240 milliliter [mL]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
History of sensitivity to heparin or heparin-induced thrombocytopenia.
History of sensitivity to local anesthetics.
History of sensitivity to any drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation

Criteria Based Upon Diagnostic Assessments:

A positive pre-study drug/alcohol screen.

Other Criteria:

Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.